 | Up a level |
2019
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A. -M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Du, K. Le, Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., Kipps, T. J., Boettcher, S., Tausch, E., Humerickhouse, R., Eichhorst, B., Wendtner, C. -M., Langerak, A. W., Kreuzer, K. -A., Ritgen, M., Goede, V., Stilgenbauer, S., Mobasher, M. and Hallek, M. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 380 (23). S. 2225 - 2237. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
2018
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D'Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Humerickhouse, R., Punnoose, E. A., Li, Y., Boyer, M., Humphrey, K., Mobasher, M. and Kater, A. P. (2018). Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med., 378 (12). S. 1107 - 1121. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
2016
Buehler, A., Wendtner, C-M, Kipps, T. J., Rassenti, L., Fraser, G. A. M., Michallet, A-S, Hillmen, P., Duerig, J., Gregory, S. A., Kalaycio, M., Aurran-Schleinitz, T., Trentin, L., Gribben, J. G., Chanan-Khan, A., Purse, B., Zhang, J., De Bedout, S., Mei, J., Hallek, M. and Stilgenbauer, S. (2016). Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J., 6. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385
Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., Palacio, C., Stehlikova, O., Kreuzer, K-A, Liptrot, S., O'Brien, D., de Tute, R. M., Marinov, I., Hauwel, M., Spacek, M., Dobber, J., Kater, A. P., Gambell, P., Soosapilla, A., Lozanski, G., Brachtl, G., Lin, K., Boysen, J., Hanson, C., Jorgensen, J. L., Stetler-Stevenson, M., Yuan, C., Broome, H. E., Rassenti, L., Craig, F., Delgado, J., Moreno, C., Bosch, F., Egle, A., Doubek, M., Pospisilova, S., Mulligan, S., Westerman, D., Sanders, C. M., Emerson, R., Robins, H. S., Kirsch, I., Shanafelt, T., Pettitt, A., Kipps, T. J., Wierda, W. G., Cymbalista, F., Hallek, M., Hillmen, P., Montserrat, E. and Ghia, P. (2016). A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia, 30 (4). S. 929 - 937. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Soumerai, J. D., Barrientos, J. C., Hallek, M., Kipps, T. J., Jones, J. A., Xing, G., Yao, N. S., Ysebaert, L., Stilgenbauer, S. and Zelenetz, A. D. (2016). AN EVALUATION OF THE CLL-IPI SCORE AND COMPREHENSIVE PROGNOSTIC FACTOR ANALYSIS IN PATIENTS WITH R/R CLL IN IDELALISIB PHASE 3 RANDOMIZED STUDIES. Haematologica, 101. S. 53 - 55. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
2014
Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H. A., Lamanna, N., Coiffier, B., Pettitt, A., Li, X., Jahn, T. M., O'Brien, S. M. and Hallek, M. J. (2014). SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL. Haematologica, 99. S. 249 - 251. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Cheson, B. D., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Lamanna, N., Hallek, M. J., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. M. and Wagner, L. I. (2014). HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS. Haematologica, 99. S. 63 - 64. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Ghia, P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Hallek, M. J., Coiffier, B., O'Brien, S. M., Stilgenbauer, S., Jiang, W., Jahn, T. M., Wong, M., Lazarov, M. and Sharman, J. P. (2014). EFFECT OF IDELALISIB/RITUXIMAB COMBINATION TREATMENT OF RELAPSED CLL ON THE BCR SIGNALING-RELATED CHEMOKINES CCL3 AND CCL4: DATA FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 56 - 58. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A. and Kroenig, H. (2014). 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia. Oncol. Res. Treat., 37. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262
Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Cheson, B. D., Ruppert, S., Kroenig, H. and Schuster, A. (2014). Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL. Oncol. Res. Treat., 37. S. 52 - 54. BASEL: KARGER. ISSN 2296-5262
Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M. and Sharman, J. P. (2014). EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 521 - 522. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stilgenbauer, S., Hallek, M. J., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Coiffier, B., O'Brien, S. M., Tausch, E., Sharman, J. P., Ruppert, S., Schuster, A. and Kroenig, H. (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262